company background image
GRTS logo

Gritstone bio NasdaqGS:GRTS Stock Report

Last Price

US$2.38

Market Cap

US$233.4m

7D

-1.2%

1Y

-2.5%

Updated

18 Mar, 2024

Data

Company Financials +

Gritstone bio, Inc.

NasdaqGS:GRTS Stock Report

Market Cap: US$233.4m

GRTS Stock Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.

GRTS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Gritstone bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gritstone bio
Historical stock prices
Current Share PriceUS$2.38
52 Week HighUS$3.33
52 Week LowUS$1.14
Beta0.40
1 Month Change10.19%
3 Month Change32.22%
1 Year Change-2.46%
3 Year Change-82.44%
5 Year Change-78.23%
Change since IPO-83.29%

Recent News & Updates

Recent updates

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14
Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Sep 26

Gritstone reaches six-month high on publication of data for cancer vaccine

Aug 16

Gritstone bio announces $80M credit facility

Jul 21

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Jul 07
Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Jul 05

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Jun 14

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Mar 17
Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Mar 05
We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Gritstone: Why The Stock Fell On Positive Data

Jan 18

Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Nov 23
Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Gritstone Poised To Dominate mRNA Market

Nov 08

Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation

Gritstone Oncology EPS beats by $0.41, beats on revenue

May 06

Gritstone files for mixed shelf offering of up to $690M

Jan 29

Gritstone Oncology +9.3% AH, EcoR1 discloses ~10% stake in company

Jan 04

Gritstone Oncology announces $125M in private placement financings

Dec 28

Here's Why Gritstone Oncology (NASDAQ:GRTS) Must Use Its Cash Wisely

Dec 24
Here's Why Gritstone Oncology (NASDAQ:GRTS) Must Use Its Cash Wisely

Shareholder Returns

GRTSUS BiotechsUS Market
7D-1.2%-2.1%-0.1%
1Y-2.5%10.4%28.4%

Return vs Industry: GRTS underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: GRTS underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is GRTS's price volatile compared to industry and market?
GRTS volatility
GRTS Average Weekly Movement18.2%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: GRTS's share price has been volatile over the past 3 months.

Volatility Over Time: GRTS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015231Andrew Allenhttps://gritstonebio.com

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.

Gritstone bio, Inc. Fundamentals Summary

How do Gritstone bio's earnings and revenue compare to its market cap?
GRTS fundamental statistics
Market capUS$233.40m
Earnings (TTM)-US$138.49m
Revenue (TTM)US$16.34m

14.3x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRTS income statement (TTM)
RevenueUS$16.34m
Cost of RevenueUS$127.18m
Gross Profit-US$110.84m
Other ExpensesUS$27.65m
Earnings-US$138.49m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.41
Gross Margin-678.16%
Net Profit Margin-847.34%
Debt/Equity Ratio77.4%

How did GRTS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.